ArticleMolecular reproduction and development2026
BGP-15 Treatment Improves Follicle Growth and Alters Collagen Deposition in Mouse Transplanted Ovaries.
Article in Molecular reproduction and development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ovarian transplantation causes a loss of follicular reserve, requiring new strategies to optimize post-transplant follicular growth. This study investigated N-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide; dihydrochloride (BGP-15), a mitochondrial modulator, as a follicular growth stimulator and a collagen-depositing inhibitor, thereby improving graft quality. In vitro, neonatal mouse ovaries were treated with different concentrations of BGP-15. In vivo, adult mice undergoing ovarian autotransplantation received 10 mg/kg of BGP-15. Follicular quantification, gene expression by qRT-PCR (Sirt1, Sirt3, Nampt, Foxo3a, KitL, Pten, Amh), collagen deposition by Picrosirius assay, neoangiogenesis, macrophage infiltration, biometric parameters, and the estrous cycle were evaluated. In vitro, 0.001 µM BGP-15 induced follicular growth. reducing the percentage of primordial follicles (p < 0.0001) and upregulating Sirt1 (p < 0.0001), Sirt3 (p = 0.026), Nampt (p = 0.002), Pten (p = 0.012), and downregulating Amh (p = 0.031). In vivo, BGP-15 treatment in transplanted mice resulted in an earlier resumption of the estrous cycle (p = 0.0458). After transplantation, BGP-15 improved follicular outcome on day 22, increasing healthy follicles (transitional p = 0.0206; primary p = 0.0125; secondary p = 0.0428) and reducing atretic follicles (p = 0.0381). Treated animals exhibited decreased macrophage numbers (p < 0.0001) and collagen deposition (ovary: p = 0.0465; capsule: p = 0.0344), and increased blood vessel density (p < 0.0001). BGP-15 improves follicular growth and survival in ovarian grafts, coinciding with mitochondrial gene dysregulation and reduced collagen deposition. These findings suggest BGP-15 as a promising candidate for improving follicular outcomes after ovarian transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.